Previous studies have demonstrated that overexpression of EpCAM is associated with poor prognosis in patients with esophageal squamous cell carcinoma (70), lung cancer (71), and breast cancer (72), and it can be used as a marker for circulating tumor cells involved in cancer cell metastasis (73). Here, EPCAM is linked to neoplasm.